News

Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer TAIPEI, TAIWAN – January 9th, 2025 – Bora Biologics, a fast-growing division of leading contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, today announced that it will support DotBio, a Singaporean biopharmaceutical company...

Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan  Taipei, Taiwan (January 6, 2025) –  Bora Pharmaceuticals Co., Ltd. (“Bora,” TWSE: 6472), a global cGMP contract development and manufacturing organization (CDMO), is pleased to announce the grand unveiling of its new small molecule dose form facility in Zhongli, Taiwan. This represents another...

Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A Ceremony: "Deal of the Year" Award and "Best Cross-Border M&A" Award   December 11, 2024 —The Taiwan Mergers & Acquisition and Private Equity Council announced its winners today in the MAPECT Award Ceremony. Among 149 M&A cases, Bora Pharmaceuticals distinguished itself by winning both the "Deal of the Year”...

Taipei, Taiwan, October 25, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors has approved the acquisition of US-based Pyros Pharmaceuticals, Inc. (“Pyros”), a specialty pharmaceutical company developing treatments for rare diseases. Founded in 2017 by Michael Smith and Edwin Urrutia, Pyros recently launched VIGAFYDETM...